BLOGS >

Prevention

RSS
A community of cardiologists and primary care physicians dedicated to the prevention of cardiovascular disease.
Avatar of JoAnne M. Foody, MD

FDA Advisers Recommend Expanded Use of Rosuvastatin (16 Dec 2009)

JoAnne M. Foody, MD

The Associated Press reports that, based on the JUPITER study, an FDA panel of advisers has recommended expansion of rosuvastatin. The FDA is expected to decide whether to act on this recommendation in 2010. According to the report, Astra Zeneca will develop an approach to use rosuvastatin in all patients at risk for heart disease based on hypertension and family history….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

  • 2 Recommendations
  • |
  • 5 Comments
Avatar of JoAnne M. Foody, MD

ARBITER 6-HALTS: Will you change your practice? Will you halt your use of ezetimibe? (16 Nov 2009)

JoAnne M. Foody, MD

ARBITER 6-HALTS provides provocative information and suggests that niacin is the preferred secondary agent once statin therapy is maxed out in high-risk CAD patients with low HDL levels (for the study, go here; for editorials, go here and here; for a summary and analysis of the study, go here; and for a question-and-answer session with the author, go here)….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

  • 1 Recommendations
  • |
  • 5 Comments
Avatar of JoAnne M. Foody, MD

Forget aspirin in primary prevention? (4 Nov 2009)

JoAnne M. Foody, MD

Recent studies (e.g., Drug and Therapeutics Bulletin 2009;47:122; Lancet 2009; 373:1849; BMJ 2008; 347:a1840) suggest that aspirin confers no benefit whatsoever in primary prevention of cardiovascular disease. The more we explore this issue, the more it appears that only individuals at intermediate or high risk are likely to benefit. We know that data in women…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

  • 4 Recommendations
  • |
  • 1 Comment
Avatar of JoAnne M. Foody, MD

Is the Framingham Risk Score Over the Hill? (30 Oct 2009)

JoAnne M. Foody, MD

The Framingham study has revolutionized our understanding of cardiovascular disease, but I wonder: is the 60-year-old study’s risk score getting a little long in the tooth? Faced with the epidemic of heart disease and growing numbers of younger people worried about heart disease risk, I find that Framingham provides me little guidance. As I see…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

  • 0 Recommendations
  • |
  • 5 Comments
Next Entries →